Cybin Therapeutics, wani kamfani na bioscience na warkewa mai zaman kansa akan manufa don ganowa da haɓaka ka'idojin warkewa na taimakon psilocybin, ya ba da lasisin PEX010 (25 mg) daga Filament don amfani a cikin gwaji. Ana sa ran za a fara gwajin a cikin Q3'22 kuma zai haɗa da mutanen da ke da babbar matsalar rashin damuwa waɗanda ke yin zaɓin magani na mai hanawa na serotonin (SSRI), wanda aka saba amfani da shi don magance bakin ciki, da kuma waɗanda suke SSRI-naive.
"Izinin Lafiyar Kanada shaida ce ga duka ingancin wannan gwaji da kuma ikon Filament na samarwa da kuma ba da lasisi ga ƴan takarar likitancin likitanci," in ji Babban Jami'in Filament, Benjamin Lightburn. "Tasirin maganin psilocybin a cikin marasa lafiya da ke shan maganin antidepressant na gargajiya na SSRI wani bincike ne mai mahimmanci kuma muna farin cikin shiga wannan muhimmin bincike."
"Yawancin mutanen Kanada da ke fama da bakin ciki suna shan maganin SSRI, kuma har ya zuwa yanzu, wannan yana nufin keɓancewa daga gwaje-gwajen asibiti na tabin hankali (PAP)," in ji Josh Taylor, Wanda ya kafa Cybin Therapeutics. "Idan za'a iya nuna cewa PAP na iya zama lafiya kuma a ba marasa lafiya akan SSRIs, da yawa za su amfana. Muna jin wannan wata babbar dama ce don nuna Lafiyar Kanada cewa Cybin Therapeutics na iya inganta sakamakon haƙuri tare da ƙungiyarmu da haɓaka ƙa'idodi. "
Filament kuma ya ba da lasisi PEX010 (25 MG) zuwa CT don ƙarin gwajin gwaji na lokaci na 2, wanda ake sa ran farawa a cikin kwata na huɗu na 2022. Dukan gwaje-gwajen Dr. Reg Peters da Dave Phillips za su jagoranci.
